HUS year 2022: Operating revenue and operating costs
Operating revenue under budget
Operating revenue amounted to EUR 2,912.9 million, falling short of the budget by 0.3% (EUR 8.1 million). The member municipalities’ contributions, EUR 1,977.7 million, exceeded the budget by 0.2% (EUR 4.1 million); this figure includes the surcharge of EUR 119.1 collected from the member municipalities.
The strike in April along with the ban on overtime and shift swaps decreased our operating revenue by an estimated EUR 41.8 million. Additionally, revenue from Covid testing was under budget by about EUR 9 million.
Binding net costs were over budget by EUR 4.1 million.
Operating costs decreased on the previous year
Operating costs amounted to EUR 2,792.8 million, being 0.6% (EUR 17.0 million) down on the previous year and under budget by 0.4% (EUR 10.1 million).
Personnel expenses
Personnel expenses were under budget by 3% (EUR 46 million).
Purchase of services
Purchase of services exceeded the budget by 4.5% (EUR 28.1 million), the most significant individual excesses being:
- ICT service outsourcing, 5.2% (EUR 10.5 million); and
- hired labor, 25.4% (EUR 8 million).
These were due for instance to the costs of the ICT change project for the health and social services reform, which had not been budgeted for, and the costs of which were covered by a central government grant. The hired labor costs exceeded the budget because of issues with personnel availability.
Purchases of medical services were over budget by 2.6% (EUR 5.1 million).
Purchases of materials, supplies and pharmaceuticals
Purchases of materials and supplies were over budget by 2.7% (EUR 13.8 million).
Purchases of drugs and pharmacy supplies were over budget by 8% (EUR 13.6 million), but on the other hand, purchases of examination and medical supplies were under budget by 4.7% (EUR 7.7 million).
The budget excess in drugs and pharmacy supplies was mostly caused by HUS Pharmacy and had to do with our national obligation to procure Covid medications and to raise the level of national preparedness in respect of certain key drugs. A central government grant was received to cover costs.
Purchases of heating and electrical power
Heating and electricity costs were over budget by 19.6% (EUR 5.1 million).
Depreciation and reductions in value
Depreciation and reductions in value exceeded the budgeted amount by 3.2% (EUR 3.4 million). Non-recurring depreciations included losses on sales of fixed assets at EUR 4.8 million, which had not been anticipated in the budget, and a reduction in value at EUR 1.0 million of the share capital of Orton Oy.